Filing Flows › Cytek Biosciences (CTKB) › Q2 2026
Cytek Biosciences (CTKB) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Cytek Biosciences (CTKB) reported revenue of $48.1M for the second quarter 2026 (Q2 2026), +6% from a year earlier and +9% from the quarter before. Operating margin was -23.7%, net loss $12.2M (25.3% of revenue).
Cytek Biosciences, Q2 2026: revenue $48.1M (+6% year over year), operating margin -23.7%, net loss $12.2M, operating cash flow $1.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $48.1M | +9% | +6% |
| Operating profit | −$11.4M | — | — |
| Net earnings | −$12.2M | — | — |
| Operating cash flow | $1.4M | — | 13× |
What changed
Revenue was $48.1M in Q2 2026, up 6% year over year and up 9% from the previous quarter. Product was the largest line at 68% of revenue. Service added $1.4M year over year (up 10%), 55% of the total change.
Gross margin was 58.9%, up 6.5 points from Q2 2025. Operating costs exceeded revenue by $11.4M, an operating margin of -23.7%. Operating expenses grew 15% against revenue growth of 6%. The fastest-growing cost line was General & admin (+24%). The quarter ended with a net loss of $12.2M, narrower than the previous quarter's $18.9M loss.
Operating cash flow was $1.4M (up 1166% year over year). Non-cash charges added back $2.0M of depreciation and amortization and $5.3M of share-based compensation. Working capital and other items added $6.2M. Capital expenditures of $2.2M exceeded it, leaving free cash flow of −$849K.
Questions
What was Cytek Biosciences' revenue in the second quarter 2026?
Cytek Biosciences (CTKB) reported revenue of $48.1M for the second quarter 2026 (Q2 2026), +6% from a year earlier and +9% from the quarter before.
Was Cytek Biosciences profitable in the second quarter 2026?
Operating loss was $11.4M (-23.7% of revenue) and net loss $12.2M.
Source: Cytek Biosciences 10-Q on SEC EDGAR.